These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 31157865)

  • 41. Interferon-gamma gene polymorphism +874 A/T is associated with an increased risk of cytomegalovirus infection among Hispanic renal transplant recipients.
    Vu D; Shah T; Ansari J; Sakharkar P; Yasir Q; Naraghi R; Hutchinson I; Min D
    Transpl Infect Dis; 2014 Oct; 16(5):724-32. PubMed ID: 25208755
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Assessment of the T-SPOT.CMV interferon-γ release assay in renal transplant recipients: A single center cohort study.
    Chanouzas D; Small A; Borrows R; Ball S
    PLoS One; 2018; 13(3):e0193968. PubMed ID: 29558479
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Factors associated with the development of cytomegalovirus infection following solid organ transplantation.
    da Cunha-Bang C; Sørensen SS; Iversen M; Sengeløv H; Hillingsø JG; Rasmussen A; Mortensen SA; Fox ZV; Kirkby NS; Christiansen CB; Lundgren JD
    Scand J Infect Dis; 2011 May; 43(5):360-5. PubMed ID: 21306196
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Preemptive anti-cytomegalovirus therapy in high-risk (donor-positive, recipient-negative cytomegalovirus serostatus) kidney transplant recipients.
    Hasegawa J; Hatakeyama S; Wakai S; Omoto K; Okumi M; Tanabe K; Mieno M; Shirakawa H
    Int J Infect Dis; 2017 Dec; 65():50-56. PubMed ID: 28986314
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Choice of antibody immunotherapy influences cytomegalovirus viremia in simultaneous pancreas-kidney transplant recipients.
    Huurman VA; Kalpoe JS; van de Linde P; Vaessen N; Ringers J; Kroes AC; Roep BO; De Fijter JW
    Diabetes Care; 2006 Apr; 29(4):842-7. PubMed ID: 16567825
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cytomegalovirus (CMV) immune monitoring with ELISPOT and QuantiFERON-CMV assay in seropositive kidney transplant recipients.
    Lee H; Park KH; Ryu JH; Choi AR; Yu JH; Lim J; Han K; Kim SI; Yang CW; Chung BH; Oh EJ
    PLoS One; 2017; 12(12):e0189488. PubMed ID: 29232714
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Incidence of cytomegalovirus in cardiac transplant recipients receiving induction immunosuppression with antithymocyte globulin.
    Jewani PK; Pouch SM; Kissling KT
    Clin Transplant; 2018 Nov; 32(11):e13420. PubMed ID: 30290013
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The Ability of a Cytomegalovirus ELISPOT Assay to Predict Outcome of Low-Level CMV Reactivation in Hematopoietic Cell Transplant Recipients.
    El Haddad L; Ariza-Heredia E; Shah DP; Jiang Y; Blanchard T; Ghantoji SS; El Chaer F; El-Haddad D; Prayag A; Nesher L; Rezvani K; Shpall E; Chemaly RF
    J Infect Dis; 2019 Feb; 219(6):898-907. PubMed ID: 30295846
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Induction immunosuppressive therapy in the elderly kidney transplant recipient in the United States.
    Gill J; Sampaio M; Gill JS; Dong J; Kuo HT; Danovitch GM; Bunnapradist S
    Clin J Am Soc Nephrol; 2011 May; 6(5):1168-78. PubMed ID: 21511836
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prospective randomized controlled trial of rabbit antithymocyte globulin compared with IL-2 receptor antagonist induction therapy in kidney transplantation.
    Pilch NA; Taber DJ; Moussa O; Thomas B; Denmark S; Meadows HB; McGillicuddy JW; Srinivas TR; Baliga PK; Chavin KD
    Ann Surg; 2014 May; 259(5):888-93. PubMed ID: 24513787
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Preemptive therapy versus valgancyclovir prophylaxis in cytomegalovirus-positive kidney transplant recipients receiving antithymocyte globulin induction.
    Couzi L; Helou S; Bachelet T; Martin S; Moreau K; Morel D; Lafon ME; Garrigue I; Merville P
    Transplant Proc; 2012 Nov; 44(9):2809-13. PubMed ID: 23146529
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Impact of donor and recipient cytomegalovirus serology on long-term survival of heart transplant recipients.
    Mabilangan C; Preiksaitis JK; Cervera C;
    Transpl Infect Dis; 2019 Feb; 21(1):e13015. PubMed ID: 30358023
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Significant Increase in Cytomegalovirus (CMV) Infection in Solid Organ Transplants Associated With Increased Use of Thymoglobulin as Induction Therapy?
    Romao EA; Yamamoto AY; Gaspar GG; Garcia TMP; Muglia VA; Nardin MEP; Molina CAF; de Figueiredo VCTP; Moyses-Neto M
    Transplant Proc; 2023 Nov; 55(9):2035-2040. PubMed ID: 37778934
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Quantity of human cytomegalovirus (CMV) DNAemia as a risk factor for CMV disease in renal allograft recipients: relationship with donor/recipient CMV serostatus, receipt of augmented methylprednisolone and antithymocyte globulin (ATG).
    Hassan-Walker AF; Kidd IM; Sabin C; Sweny P; Griffiths PD; Emery VC
    J Med Virol; 1999 Jun; 58(2):182-7. PubMed ID: 10335868
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Impact of a preemptive strategy after 3 months of valganciclovir cytomegalovirus prophylaxis in kidney transplant recipients.
    Boillat Blanco N; Pascual M; Venetz JP; Nseir G; Meylan PR; Manuel O
    Transplantation; 2011 Jan; 91(2):251-5. PubMed ID: 21099744
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Risk factors and impact of cytomegalovirus disease in simultaneous pancreas-kidney transplantation.
    Kaufman DB; Leventhal JR; Gallon LG; Parker MA; Koffron AJ; Fryer JP; Abecassis MM; Stuart FP
    Transplantation; 2001 Dec; 72(12):1940-5. PubMed ID: 11773893
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Low-dose rabbit antithymocyte globulin versus basiliximab induction therapy in low-risk renal transplant recipients: 8-year follow-up.
    Laftavi MR; Alnimri M; Weber-Shrikant E; Kohli R; Said M; Patel S; Pankewycz O
    Transplant Proc; 2011 Mar; 43(2):458-61. PubMed ID: 21440733
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Post-renal transplant cytomegalovirus infection: study of risk factors.
    Kute VB; Vanikar AV; Shah PR; Gumber MR; Patel HV; Godara SM; Munjappa BC; Sainaresh VV; Engineer DP; Jain SH; Modi PR; Shah VR; Trivedi VB; Trivedi HL
    Transplant Proc; 2012 Apr; 44(3):706-9. PubMed ID: 22483473
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The impact of terminal complement blockade on the efficacy of induction with polyclonal rabbit antithymocyte globulin in living donor renal allografts.
    Goh BK; Chedid MF; Gloor JM; Raghavaiah S; Stegall MD
    Transpl Immunol; 2012 Oct; 27(2-3):95-100. PubMed ID: 22813834
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Incidence and outcomes of cytomegalovirus in pancreas transplantation with steroid-free immunosuppression.
    Shah AP; Chen JM; Fridell JA
    Clin Transplant; 2015 Dec; 29(12):1221-9. PubMed ID: 26458498
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.